NY-ESO-1 Protein Vaccine
Sponsors
Ludwig Institute for Cancer Research
Conditions
TumorsUnresectable or Metastatic Melanoma
Phase 1
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
CompletedNCT00299728
Start: 2006-03-21End: 2014-01-10Updated: 2022-10-10
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
TerminatedNCT01810016
Start: 2014-01-24End: 2016-05-17Updated: 2022-10-12